These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 15472034)

  • 1. Assessment of urinary bone markers for monitoring treatment of osteoporosis.
    Worsfold M; Powell DE; Jones TJ; Davie MW
    Clin Chem; 2004 Dec; 50(12):2263-70. PubMed ID: 15472034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of urinary N-telopeptide of type I collagen measurements in the management of osteoporosis in clinical practice.
    Baxter I; Rogers A; Eastell R; Peel N
    Osteoporos Int; 2013 Mar; 24(3):941-7. PubMed ID: 22872068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urinary N-telopeptide levels discriminate normal, osteopenic, and osteoporotic bone mineral density.
    Schneider DL; Barrett-Connor EL
    Arch Intern Med; 1997 Jun; 157(11):1241-5. PubMed ID: 9183236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The predictive value of biochemical markers of bone turnover for bone mineral density in postmenopausal Japanese women.
    Chaki O; Yoshikata I; Kikuchi R; Nakayama M; Uchiyama Y; Hirahara F; Gorai I
    J Bone Miner Res; 2000 Aug; 15(8):1537-44. PubMed ID: 10934652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response of biochemical markers of bone turnover to hormone replacement therapy: impact of biological variability.
    Hannon R; Blumsohn A; Naylor K; Eastell R
    J Bone Miner Res; 1998 Jul; 13(7):1124-33. PubMed ID: 9661076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The relationship of biochemical markers of bone turnover to bone density changes in postmenopausal women: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial.
    Marcus R; Holloway L; Wells B; Greendale G; James MK; Wasilauskas C; Kelaghan J
    J Bone Miner Res; 1999 Sep; 14(9):1583-95. PubMed ID: 10469288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation.
    Rosen CJ; Chesnut CH; Mallinak NJ
    J Clin Endocrinol Metab; 1997 Jun; 82(6):1904-10. PubMed ID: 9177404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urinary bone resorption markers in monitoring treatment of symptomatic osteoporosis.
    Parviainen MT; Jääskeläinen K; Kröger H; Arnala I; Alhava E
    Clin Chim Acta; 1999 Jan; 279(1-2):145-54. PubMed ID: 10064126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early changes in urinary cross-linked N-terminal telopeptides of type I collagen level correlate with 1-year response of lumbar bone mineral density to alendronate in postmenopausal Japanese women with osteoporosis.
    Iwamoto J; Takeda T; Sato Y; Uzawa M
    J Bone Miner Metab; 2005; 23(3):238-42. PubMed ID: 15838627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis.
    Chen P; Satterwhite JH; Licata AA; Lewiecki EM; Sipos AA; Misurski DM; Wagman RB
    J Bone Miner Res; 2005 Jun; 20(6):962-70. PubMed ID: 15883636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hormone replacement therapy in postmenopausal women: urinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density.
    Chesnut CH; Bell NH; Clark GS; Drinkwater BL; English SC; Johnson CC; Notelovitz M; Rosen C; Cain DF; Flessland KA; Mallinak NJ
    Am J Med; 1997 Jan; 102(1):29-37. PubMed ID: 9209198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of alendronate and hormone replacement therapy, alone and in combination, on bone mass and markers of bone turnover in elderly women with osteoporosis.
    Eviö S; Tiitinen A; Laitinen K; Ylikorkala O; Välimäki MJ
    J Clin Endocrinol Metab; 2004 Feb; 89(2):626-31. PubMed ID: 14764773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Change of cross-linked telopeptide of type I collagen (ICTP) and other bone resorption markers in patients with bone fragility fractures.
    Takahara K; Kamimura M; Hashidate H; Uchiyama S; Nakagawa H
    J Orthop Sci; 2007 May; 12(3):219-26. PubMed ID: 17530373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Longitudinal changes in bone mineral density and bone turnover in postmenopausal women with primary hyperparathyroidism.
    Guo CY; Thomas WE; al-Dehaimi AW; Assiri AM; Eastell R
    J Clin Endocrinol Metab; 1996 Oct; 81(10):3487-91. PubMed ID: 8855790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New biochemical markers of bone resorption in the study of postmenopausal osteoporosis.
    de la Piedra C; Traba ML; Dominguez Cabrera C; Sosa Henríquez M
    Clin Chim Acta; 1997 Sep; 265(2):225-34. PubMed ID: 9385464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monitoring alendronate therapy for osteoporosis.
    Braga de Castro Machado A; Hannon R; Eastell R
    J Bone Miner Res; 1999 Apr; 14(4):602-8. PubMed ID: 10234582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical evaluation of the Serum CrossLaps One Step ELISA, a new assay measuring the serum concentration of bone-derived degradation products of type I collagen C-telopeptides.
    Christgau S; Rosenquist C; Alexandersen P; Bjarnason NH; Ravn P; Fledelius C; Herling C; Qvist P; Christiansen C
    Clin Chem; 1998 Nov; 44(11):2290-300. PubMed ID: 9799756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating levels of osteoclast activating cytokines, interleukin-11 and transforming growth factor-beta2, as valuable biomarkers for the assessment of bone turnover in postmenopausal osteoporosis.
    Shaarawy M; Zaki S; Sheiba M; El-Minawi AM
    Clin Lab; 2003; 49(11-12):625-36. PubMed ID: 14651333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of hormone replacement therapy in postmenopausal women on urinary C-telopeptide and N-telopeptide of type I collagen, new markers of bone resorption.
    Taga M; Uemura T; Minaguchi H
    J Endocrinol Invest; 1998 Mar; 21(3):154-9. PubMed ID: 9591210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment.
    Garnero P; Shih WJ; Gineyts E; Karpf DB; Delmas PD
    J Clin Endocrinol Metab; 1994 Dec; 79(6):1693-700. PubMed ID: 7989477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.